Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Ratio Therapeutics

Ratio Therapeutics

Series CUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$70.0Msum of rounds with a disclosed amount only
Named investors
4
Financing history
1 rounds
  1. Jul 31, 2026
    Series C · $70.0M (disclosed)
    Duquesne Family Office (participant) via Sue MengBristol Myers Squibb (participant)Eli Lilly (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure”
Investors on record
4 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Jul 31, 2026
    Ratio Therapeutics announced Series C of $70,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
3 observations
Every observation on this company